| Literature DB >> 34905975 |
Sean C Broomhead1,2,3, Maurice Mars1,4, Richard E Scott1,5, Tom Jones3.
Abstract
eHealth is an opportunity cost, competing for limited available funds with other health priorities such as clinics, vaccinations, medicines and even salaries. As such, it should be appraised for probable impact prior to allocation of funds. This is especially pertinent as recognition grows for the role of eHealth in attaining Universal Health Coverage. Despite optimism about eHealth's potential role, in Africa there remain insufficient data and skills for adequate economic appraisals to select optimal investments from numerous competing initiatives. The aim of this review is to identify eHealth investment appraisal approaches and tools that have been used in African countries, describe their characteristics and make recommendations regarding African eHealth investment appraisal in the face of limited data and expertise.Entities:
Keywords: Africa; appraisal; assessment; developing countries; digital health; eHealth; economics; impact; investment
Mesh:
Substances:
Year: 2021 PMID: 34905975 PMCID: PMC8679012 DOI: 10.1177/00469580211059999
Source DB: PubMed Journal: Inquiry ISSN: 0046-9580 Impact factor: 1.730
Economic Evaluations Checklists.
| Checklist questions |
|---|
| JBI checklist for economic evaluations |
| 1. Is there a well-defined question? |
| 2. Is there comprehensive description of alternatives? |
| 3. Are all important and relevant costs and outcomes for each alternative identified? |
| 4. Has clinical effectiveness been established? |
| 5. Are costs and outcomes measured accurately? |
| 6. Are costs and outcomes valued credibly? |
| 7. Are costs and outcomes adjusted for differential timing? |
| 8. Is there an incremental analysis of costs and consequences? |
| 9. Were sensitivity analyses conducted to investigate uncertainty in estimates of cost or consequences? |
| 10. Do study results include all issues of concern to users? |
| 11. Are the results generalisable to the setting of interest in the review? |
| 12. Overall appraisal: Include, exclude or seek further info |
| FCM-DH checklist for digital health economic evaluations |
| 1. Is there a case for change? |
| 2. Is there a strategic fit between the health strategy and the digital health initiative? |
| 3. Is there an analysis of options? |
| 4. Are costs and benefits identified? |
| 5. Is there a sensitivity analysis? |
| 6. Is the risk exposure addressed? |
| 7. Is there an adjustment for optimism bias? |
| 8. Is affordability addressed? |
| 9. Is there a practical plan for delivery? |
| 10. Are clear delivery milestones provided? |
| 11. Is change management addressed? |
| 12. Is there a procurement plan? |
| 13. Is there a plan for building partnerships? |
Figure 1.Flow diagram of search process.
List and Characteristics of Selected Papers.
| Author | Bowser, 2018 | Datta, 2016 | Mangone, 2016 | Larsen-Cooper, 2015 | Chang, 2015 |
|---|---|---|---|---|---|
| Title | Cost-Effectiveness of Mobile Health for
Antenatal Care and Facility Births in Nigeria
| A Roadmap and Cost Implications of Establishing
Comprehensive Cancer Care Using a Teleradiotherapy Network
in a Group of Sub-Saharan African Countries With No Access
to Radiation Therapy
| Sustainable Cost Models for mHealth at Scale:
Modelling Program Data from m4RH Tanzania
| Scale Matters: A Cost-Outcome Analysis of an
mHealth Intervention in Malawi
| Cost analyses of peer health worker and mHealth
support interventions for improving AIDS care in Rakai, Uganda
|
| African country/ies | Nigeria | Benin, Burkina Faso, Guinea, Niger, Togo, Central African Republic, Chad, Democratic Republic of Congo, Rwanda and Burundi | Tanzania | Malawi | Uganda |
| African region | West Africa | Francophone Africa, including West, Central and East Africa | East Africa | Southern Africa | East Africa |
| Digital health initiative | mHealth | Teleradiotherapy | mHealth | mHealth | mHealth |
| Clinical discipline | RMNCH | Radiation therapy | RMNCH | RMNCH | AIDS care |
| Investment appraisal method | Cost-effectiveness analysis and cost-effectiveness ratio; retrospective | Costing | Break-even analyses and Monte Carlo uncertainty analysis | Cost-outcome analysis | Costing |
Characteristics of Investment Appraisal Checklists.
| Question | Bowser, 2018 | Datta, 2016 | Mangone, 2016 | Larsen-Cooper, 2015 | Chang, 2015 | Total “yes” |
|---|---|---|---|---|---|---|
| JBI checklist for economic evaluations | ||||||
| 1. Is there a well-defined question? | Yes | Yes | Yes | Yes | Yes | 5 |
| 2. Is there comprehensive description of alternatives? | Yes | No | Yes | Yes | Yes | 4 |
| 3. Are all important and relevant costs and outcomes for each alternative identified? | Yes | No | No | Yes | No | 2 |
| 4. Has clinical effectiveness been established? | Yes | No | No | No | No | 1 |
| 5. Are costs and outcomes measured accurately? | Yes | No | No | Yes | No | 2 |
| 6. Are costs and outcomes valued credibly? | Yes | No | No | No | No | 1 |
| 7. Are costs and outcomes adjusted for differential timing? | No | No | No | Yes | No | 1 |
| 8. Is there an incremental analysis of costs and consequences? | Yes | No | No | No | Yes | 2 |
| 9. Were sensitivity analyses conducted to investigate uncertainty in estimates of cost or consequences? | Yes | No | Yes | Yes | Yes | 4 |
| 10. Do study results include all issues of concern to users? | No | No | No | No | No | 0 |
| 11. Are the results generalisable to the setting of interest in the review? | No | Yes | Yes | No | No | 2 |
| Total “yes” | 8 (73%) | 2 (18%) | 4 (36%) | 6 (55%) | 4 (36%) | 24 (44%) |
| FCM-DH checklist for digital health economic evaluations | ||||||
| 1. Is there a case for change? | Yes | Yes | Yes | Yes | No | 4 |
| 2. Is there a strategic fit between the health strategy and the digital health initiative? | Yes | Yes | Yes | Yes | No | 4 |
| 3. Is there an analysis of options? | No | No | Yes | No | No | 1 |
| 4. Are costs and benefits identified? | Yes | No | No | Yes | Yes | 3 |
| 5. Is there a sensitivity analysis? | Yes | No | Yes | Yes | Yes | 4 |
| 6. Is the risk exposure addressed? | No | No | No | No | No | 0 |
| 7. Is there an adjustment for optimism bias? | No | No | No | No | No | 0 |
| 8. Is affordability addressed? | No | No | No | No | No | 0 |
| 9. Is there a practical plan for delivery? | No | No | No | No | No | 0 |
| 10. Are clear delivery milestones provided? | No | No | No | No | No | 0 |
| 11. Is change management addressed? | No | No | No | No | No | 0 |
| 12. Is there a procurement plan? | No | No | No | No | No | 0 |
| 13. Is there a plan for building partnerships? | No | No | Yes | No | No | 1 |
| Total ‘yes’ | 4 (31%) | 2 (15%) | 5 (38%) | 4 (31%) | 2 (15%) | 17 (26%) |
| Total ‘yes’ for both checklists | 50% | 17% | 38% | 42% | 25% | 34% |